Type 1 Diabetes (Juvenile Diabetes) 2018 Pipeline Review, Therapeutic Development & Assessment, Key Players Inolved and Drug Profiles - ResearchAndMarkets.com
Jun. 12, 2018
DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type1 diabetes (Juvenile Diabetes) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 11, 33, 29, 2, 102, 32 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 30 and 4 molecules, respectively.
Companies MentionedAdocia SAS AiCuris GmbH & Co KG Allist Shanghai Pharmaceutical Technology Co Ltd Amarantus Bioscience Holdings Inc Amarna Therapeutics BV apceth Biopharma GmbH Aphios Corp Apodemus AB Arecor Ltd Astellas Pharma Inc AstraZeneca Plc Atlantic Bio Sci LLC Axxam SpA Beta-Cell NV Biocon Ltd BioLineRx Ltd BioLingus AG Biozeus BirchBioMed Inc Boehringer Ingelheim GmbH Boston Therapeutics Inc BTB Pharma AB Caladrius Biosciences Inc Cancer Prevention Pharmaceuticals Inc Cellix Bio Pvt Ltd Compugen Ltd Daewoong Pharmaceutical Co Ltd Eli Lilly and Co GlaxoSmithKline Plc Johnson & Johnson Merck & Co Inc Novo Nordisk AS Pfizer Inc Sanofi
Key Topics CoveredIntroduction Type1 diabetes (Juvenile Diabetes) - Overview Type1 diabetes (Juvenile Diabetes) - Therapeutics Development Type1 diabetes (Juvenile Diabetes) - Therapeutics Assessment Type1 diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development Type1 diabetes (Juvenile Diabetes) - Drug Profiles Type1 diabetes (Juvenile Diabetes) - Dormant Projects Type1 diabetes (Juvenile Diabetes) - Discontinued Products Type1 diabetes (Juvenile Diabetes) - Product Development Milestones Appendix
For more information about this report visit https://www.researchandmarkets.com/research/k5295z/type_1_diabetes?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180612005779/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL DIABETES
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/12/2018 07:42 AM/DISC: 06/12/2018 07:42 AM